Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delbert G Robinson

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Psychiatry Research|June 4, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomesSerge Sevy, Delbert G Robinson, Suzanne Sunday, et al.
Human Brain Mapping|August 31, 2018
Frequency specific resting state functional abnormalities in psychosisSuril Gohel, Juan A Gallego, Delbert G Robinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 22, 2010
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studiesTerry E Goldberg, Richard S E Keefe, Robert S Goldman, et al.
Schizophrenia Bulletin|August 29, 2015
Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset SchizophreniaDaniel J Coletti, Mary Brunette, Majnu John, et al.
Human Brain Mapping|March 6, 2010
Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteersBabak A Ardekani, Ali Tabesh, Serge Sevy, et al.
The Journal of Clinical Psychiatry|May 4, 2019
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE TrialJohn M Kane, Nina R Schooler, Patricia Marcy, et al.
The American Journal of Psychiatry|May 3, 2016
Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP ResultsJohn M Kane, Delbert G Robinson, Nina R Schooler, et al.
Pharmacogenetics and Genomics|July 29, 2010
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophreniaTodd Lencz, Delbert G Robinson, Barbara Napolitano, et al.
The International Journal of Neuropsychopharmacology|December 4, 2012
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisJian-Ping Zhang, Juan A Gallego, Delbert G Robinson, et al.
Advances in Therapy|March 11, 2023
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of SchizophreniaDelbert G Robinson, Mark Suett, Amanda Wilhelm, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Psychiatry Research|June 4, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomesSerge Sevy, Delbert G Robinson, Suzanne Sunday, et al.
Human Brain Mapping|August 31, 2018
Frequency specific resting state functional abnormalities in psychosisSuril Gohel, Juan A Gallego, Delbert G Robinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 22, 2010
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studiesTerry E Goldberg, Richard S E Keefe, Robert S Goldman, et al.
Schizophrenia Bulletin|August 29, 2015
Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset SchizophreniaDaniel J Coletti, Mary Brunette, Majnu John, et al.
Human Brain Mapping|March 6, 2010
Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteersBabak A Ardekani, Ali Tabesh, Serge Sevy, et al.
The Journal of Clinical Psychiatry|May 4, 2019
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE TrialJohn M Kane, Nina R Schooler, Patricia Marcy, et al.
The American Journal of Psychiatry|May 3, 2016
Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP ResultsJohn M Kane, Delbert G Robinson, Nina R Schooler, et al.
Pharmacogenetics and Genomics|July 29, 2010
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophreniaTodd Lencz, Delbert G Robinson, Barbara Napolitano, et al.
The International Journal of Neuropsychopharmacology|December 4, 2012
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisJian-Ping Zhang, Juan A Gallego, Delbert G Robinson, et al.
Advances in Therapy|March 11, 2023
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of SchizophreniaDelbert G Robinson, Mark Suett, Amanda Wilhelm, et al.
Pageof 11